Bonmax 150 mg (Tablet)
1 tablet kit: ৳ 510.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Globe pharmaceuticals ltd |
Indications
- Treatment of osteoporosis in women (specially postmenopausal)
- Prevention of osteoporosis in women (specially postmenopausal)
- Prevention and treatment of osteoporosis in men
- Confirmation of osteoporosis by low bone mass (T-score <-2.0 SD) and the presence or history of osteoporotic fracture
Pharmacology
- Inhibition of bone resorption
- Prevention of experimentally induced bone destruction
- Inhibition of osteoclastic activity
- High potency and therapeutic margin
- High affinity for hydroxyapatite
- Reduction of bone resorption without affecting bone formation
- Reduction of elevated rate of bone turnover in postmenopausal women
- Progressive net gain in bone mass with daily or intermittent administration
- Reduced bone resorption reflected in serum and urinary biochemical markers
Dosage & Administration
- Recommended dose of one 150 mg film-coated tablet once a month
- Tablet should be taken 60 minutes before the first food or drink of the day
- Tablet should be swallowed whole with a full glass of plain water (180 to 240 ml)
- Patients should not lie down for 60 minutes after taking the tablet
- Plain water is the only drink to be taken with the tablet
- Instruction for missed dose and supplemental calcium or vitamin D
Interaction
- Interference of calcium supplements, antacids, and some oral medications with absorption
- Absence of interaction potential with tamoxifen or hormone replacement therapy
- Increase in bioavailability due to i.v. ranitidine
- No drug interactions of clinical significance likely
- Similar incidence of upper gastrointestinal events with aspirin or NSAIDs
Contraindications
- Known hypersensitivity to ibandronic acid or excipients
- Uncorrected hypocalcemia
- Abnormalities of the esophagus delaying esophageal emptying
- Inability to stand or sit upright for at least 60 minutes
Side Effects
- Dyspepsia
- Nausea
- Diarrhea
- Abdominal pain
- Muscle aches
- Headaches
- Dizziness
Pregnancy & Lactation
- Not to be used during pregnancy
- No evidence for direct fetal toxic or teratogenic effect in rats and rabbits
- No clinical experience in pregnant women
- Not to be used during lactation
- Concentration of ibandronic acid in breast milk and plasma
Precautions & Warnings
- Effective treatment of hypocalcemia and other disturbances of bone and mineral metabolism before starting therapy
- Adequate intake of calcium and vitamin D is important
- Possible irritant effects on upper gastrointestinal mucosa
- Risk of severe esophageal adverse experiences
- Caution with concomitant medication with NSAIDs
- Osteonecrosis of the jaw (ONJ) in patients treated with bisphosphonates
- No established safety and efficacy for patients less than 18 years old
Use in Special Populations
- No dosage adjustment for patients with mild or moderate renal impairment
- Individual risk-benefit assessment for creatinine clearance below 30 ml/min
- No dosage adjustment necessary for patients with hepatic impairment
- No dosage adjustment necessary for elderly patients
- Safety and efficacy not established in patients less than 18 years old
Overdose Effects
- Upper gastrointestinal adverse events
- Use of milk or antacids to bind Bonmax
- Risk of esophageal irritation
Therapeutic Class
- Bisphosphonate preparations
Storage Conditions
- Keep below 30°C temperature
- Away from light & moisture
- Keep out of the reach of children